加拿大慢性肝炎B相关肝细胞癌患者的流行病学,治疗模式和生存率
Y Sachar1, S E Congly2, K W Burak2
1Department of Medicine, Division of Gastroenterology and Multi-Organ Transplant Unit, London Health Sciences Center, Western University, London, Ontario, Canada.
Journal of viral hepatitis
|August 16, 2024
概括
通过监测及早发现可显著改善慢性乙型肝炎 (CHB) 患者的存活率,这些患者患有肝细胞癌 (HCC). 这项加拿大研究强调了CHB相关的肝癌的有效管理策略.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 流行病学 流行病学
背景情况:
- 慢性乙型肝炎 (CHB) 是肝细胞癌 (HCC) 的全球主要驱动因素.
- 了解加拿大的CHB-HCC患者的治疗结果对于公共卫生至关重要.
- 这项研究分析了加拿大的大量队列,以详细说明CHB-HCC患者的特征和生存率.
研究的目的:
- 描述和评估加拿大的CHB-HCC患者的结果.
- 确定影响CHB-HCC患者生存的因素.
- 评估监测对早期HCC检测和患者存活率的影响.
主要方法:
- 使用加拿大乙型肝炎网络注册表 (2012-2022) 的回顾性横截面队列研究.
- 包括6711个单一感染CHB的受试者;232个开发HCC.
- 使用R版本2.2进行描述性分析,奇平方建模和多变量生存分析.
主要成果:
- 92%的CHB-HCC患者患有晚期肝病 (纤维化阶段F3+).
- 早期HCC (BCLC 0-A) 在81%的患者中被检测出来,其中53%通过监测诊断出来.
- 在HCC诊断后观察到78.7%的生存率,查与改善的生存率有显著的相关性.
结论:
- 监测计划对于在CHB患者中早期发现HCC至关重要.
- 早期诊断和治愈治疗的意图导致了有利的生存结果.
- 这一加拿大队列证明了CHB-HCC主动管理的有效性.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.8K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
398
相关概念视频
01:21Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:29Chronic Pancreatitis II: Collaborative Care
79
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
79